MWNA
CARM

Marshall Wace North America’s Carisma Therapeutics CARM Stock Holding History

Marshall Wace North America’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$311K Buy
+19,661
New +$944K ﹤0.01% 1232

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Marshall Wace North America's CARM Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Carisma Therapeutics (CARM) in Q3 2021: 19,661 shares worth $311K. The stake represents ﹤0.01% of the portfolio and ranks #1232 among its holdings.

103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

  • Marshall Wace North America held 19,661 shares of Carisma Therapeutics worth $311K as of Q3 2021.
  • Carisma Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Carisma Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1232 holding.
  • 103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.